Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00601198 · ClinicalTrials.gov registry record · Phase 2
A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer
A Phase 2 study, sponsored by University of Cincinnati.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT00601198 is a Phase 2 study that was terminated before completion, run by University of Cincinnati. The registered enrollment target is 4 participants.
The verdict
NCT00601198, a Phase 2 study, was terminated before completion, sponsored by University of Cincinnati.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effect of amifostine (ETHYOL) on decreasing the rate and severity of nerve dysfunction or neuropathy (numbness and tingling in hands and feet) associated with FOLFOX chemotherapy.
Interventions
- DRUG Amifostine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2006-10 |
| Est. Completion | 2010-01-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00601198
The ClinicalTrials.gov registry entry for NCT00601198 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Amifostine is the first listed.
NCT00601198 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00601198 about?
NCT00601198 is a clinical study titled "A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer". The purpose of this study is to determine the effect of amifostine (ETHYOL) on decreasing the rate and severity of nerve dysfunction or neuropathy (numbness and tingling in hands and feet) associated with FOLFOX chemotherapy.
What is the current status of trial NCT00601198?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2006-10. Estimated completion is 2010-01-13.
What interventions are being tested in trial NCT00601198?
The interventions under investigation include: Amifostine (DRUG).
Who is sponsoring clinical trial NCT00601198?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.